Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profile.
Jojima T, Sakurai S, Kishi H, Kato K, Iijima T, Tomaru T, Usui I, Aso Y. Jojima T, et al. Among authors: aso y. Expert Opin Pharmacother. 2024 May 29. doi: 10.1080/14656566.2024.2362265. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38809611
Status epilepticus with unilateral brain edema in COVID-19.
Aso Y, Masuda T, Kimura N, Matsubara E. Aso Y, et al. Intern Med. 2024 May 2. doi: 10.2169/internalmedicine.3080-23. Online ahead of print. Intern Med. 2024. PMID: 38692917 Free article. No abstract available.
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R, Ishihara S, Tsuboi Y, Katsuno M, Nakagawa M, Matsushita T, Aso Y, Matsuura E, Tokashiki T, Mukaino A, Adachi H, Nakanishi K, Yamaguchi Y, Yamaguchi S, Yamano Y. Sato T, et al. Among authors: aso y. J Neurol. 2024 Jun;271(6):3471-3485. doi: 10.1007/s00415-024-12239-x. Epub 2024 Mar 2. J Neurol. 2024. PMID: 38430272 Clinical Trial.
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.
Wakamatsu S, Jojima T, Hashiguchi M, Kishi H, Niitani T, Sakurai S, Iijima T, Kogai T, Tomaru T, Usui I, Aso Y. Wakamatsu S, et al. Among authors: aso y. J Diabetes Complications. 2024 Jan;38(1):108650. doi: 10.1016/j.jdiacomp.2023.108650. Epub 2023 Nov 23. J Diabetes Complications. 2024. PMID: 38035640
889 results